



For Immediate Release

Contact: Craig Orfield
(202) 224-6770

Wednesday, May 2, 2007

ENZI SUPPORTS AMENDMENT TO PROTECT WOMEN'S HEALTH

Washington D.C. – U.S. Senator Mike Enzi, R-WY, Ranking Member of the Senate Health, Education, Labor and Pensions Committee (HELP Committee), today voiced his strong support for an amendment to the drug safety bill that would require the Food and Drug Administration (FDA) to review the drug RU-486 by a specific date, but in the same manner that it reviews all other drugs with increased risks.

“Congress would be falling down on the job if we did not take this opportunity to protect all women from high risk drugs like RU-486,” Enzi said.

“RU-486 presents potentially serious health risks to women all across the country, yet those risks were never properly evaluated before the Clinton Administration used improper mechanisms at FDA to allow the drug to enter the market,” Enzi said. “This amendment will not ban RU-486; it simply allows FDA to evaluate the drug in a manner that is consistent with the assessment process for drugs that pose similar levels of risk.”

“Every other drug that has restrictions on the distribution of its use will have to have this assessment, and RU-486 should not be any different.”

The amendment, offered by Senator Jim DeMint, R-SC, would require FDA to conduct a proper assessment of RU-486 seven months after the bill is enacted.

#####